CRDL: Cardiol Therapeutics Inc - Class A

CRDL新闻

• 13:07 Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
• 12:37 Cardiol Therapeutics发布二期心肌炎研究结果
• 12:36 Cardiol Therapeutics publishes phase II myocarditis study results
• 21:20 Cardiol Therapeutics提交包销协议和权证契约
• 21:19 Cardiol Therapeutics files underwriting agreement and warrant indenture
• 13:58 Cardiol Therapeutics宣布1350万美元私募配售
• 13:57 Cardiol Therapeutics announces $13.5 million private placement
• 13:51 Cardiol Therapeutics宣布1350万美元包销融资
• 13:49 Cardiol Therapeutics announces $13.5 million bought deal financing
• 12:43 Cardiol Therapeutics在复发性心包炎试验中达到50%入组率
• 12:41 Cardiol Therapeutics reaches 50% enrollment in recurrent pericarditis trial
• 12:39 H.C. Wainwright重申Cardiol Therapeutics股票买入评级，目标价9美元
• 12:36 H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target
• 07:11 Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket - Ambitions Enterprise Mgmt (NASDAQ:AHMA), American Bitcoin (NASDAQ:ABTC)
• 15:29 New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
• 12:34 Cardiol Therapeutics reports positive Phase II myocarditis trial results
• 12:54 Cardiol Therapeutics获美国专利批准用于心脏疾病治疗
• 12:53 Cardiol Therapeutics receives U.S. patent allowance for heart treatments